NASDAQ:PYPD PolyPid (PYPD) Stock Price, News & Analysis $3.20 -0.34 (-9.60%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About PolyPid Stock (NASDAQ:PYPD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PolyPid alerts:Sign Up Key Stats Today's Range$3.20▼$3.5550-Day Range$3.15▼$3.6852-Week Range$2.95▼$9.20Volume7,749 shsAverage Volume6,179 shsMarket Capitalization$15.35 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingBuy Company OverviewPolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Read More… $5k to $1.3m in just 3 trades (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. PolyPid Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks53rd Percentile Overall ScorePYPD MarketRank™: PolyPid scored higher than 53% of companies evaluated by MarketBeat, and ranked 543rd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPolyPid has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePolyPid has only been the subject of 1 research reports in the past 90 days.Read more about PolyPid's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PolyPid are expected to grow in the coming year, from ($4.39) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PolyPid is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PolyPid is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about PolyPid's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.21% of the float of PolyPid has been sold short.Short Interest Ratio / Days to CoverPolyPid has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PolyPid has recently increased by 6.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPolyPid does not currently pay a dividend.Dividend GrowthPolyPid does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.21% of the float of PolyPid has been sold short.Short Interest Ratio / Days to CoverPolyPid has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PolyPid has recently increased by 6.85%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News SentimentN/A News SentimentPolyPid has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for PolyPid this week, compared to 1 article on an average week.MarketBeat Follows1 people have added PolyPid to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PolyPid insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 26.47% of the stock of PolyPid is held by institutions.Read more about PolyPid's insider trading history. Receive PYPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter. Email Address PYPD Stock News HeadlinesPolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024October 30 at 8:00 AM | globenewswire.comRosalind Advisors, Inc. Reduces Stake in PolyPid LtdOctober 24, 2024 | finance.yahoo.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…October 31, 2024 | WealthPress (Ad)PolyPid announces publication in IJS on Phase 3 SHIELD I trial of D-PLEX100October 22, 2024 | markets.businessinsider.comPolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal SurgeryOctober 21, 2024 | globenewswire.comPolyPid retains stock target, buy rating on positive trial enrollment updateOctober 4, 2024 | investing.comPolyPid completes enrollment for phase 3 trialOctober 3, 2024 | uk.investing.comBuy Rating Affirmed for PolyPid on D-PLEX’s Positive Trial Milestones and Commercial ProspectsOctober 3, 2024 | markets.businessinsider.comSee More Headlines PYPD Stock Analysis - Frequently Asked Questions How have PYPD shares performed this year? PolyPid's stock was trading at $3.80 at the beginning of 2024. Since then, PYPD shares have decreased by 15.8% and is now trading at $3.20. View the best growth stocks for 2024 here. How were PolyPid's earnings last quarter? PolyPid Ltd. (NASDAQ:PYPD) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.51) by $0.26. When did PolyPid's stock split? Shares of PolyPid reverse split on Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did PolyPid IPO? PolyPid (PYPD) raised $50 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 3,100,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers. Who are PolyPid's major shareholders? Top institutional investors of PolyPid include Rosalind Advisors Inc. (14.16%). How do I buy shares of PolyPid? Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of PolyPid own? Based on aggregate information from My MarketBeat watchlists, some other companies that PolyPid investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Teladoc Health (TDOC), CrowdStrike (CRWD), PayPal (PYPL) and Roku (ROKU). Company Calendar Last Earnings8/14/2024Today10/31/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:PYPD CUSIPN/A CIK1611842 Webwww.polypid.com Phone972-74-719-5700FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$14.00 Low Stock Price Target$14.00 Potential Upside/Downside+295.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($9.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-969.85% Return on Assets-121.65% Debt Debt-to-Equity Ratio1.95 Current Ratio0.95 Quick Ratio0.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-2.79Miscellaneous Outstanding Shares4,797,000Free Float3,612,000Market Cap$16.98 million OptionableNo Data Beta1.32 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:PYPD) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.